FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 344:1782-1784 June 7, 2001 Number 23 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Roth, D. A. PubMed Citation

The current treatment of hemophilia, whether due to a deficiency of factor VIII or factor IX — as reviewed in this issue of the Journal ¹ — consists of periodic replacement of the deficient factor with human blood products or recombinant proteins that have been synthesized in tissue culture. Ideally, there should be continuous endogenous production of these factors to protect against bleeding and to minimize exposure to infectious agents that may be present in replacement therapies. Theoretically, this goal can be achieved with gene therapy. The hemophilias are attractive candidates for gene therapy: the wide range of serum levels of . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Dhar, P., Abramovitz, S., DiMichele, D., Gibb, C. B., Gadalla, F. (2003). Management of pregnancy in a patient with severe haemophilia A. Br J Anaesth 91: 432-435 [Abstract] [Full Text]